The dog-loving world went into meltdown recently, with the announcement of a brand new drug to help increase the life expectancy of large-breed dogs.
The company behind it, Loyal, is on the path to getting conditional approval from the US FDA for LOY-001 and has just started a new study for a pill that’d see our smaller four-legged friends live longer.
On today’s episode of The Briefing, we chat with Brennen McKenzie, the Director of Veterinary Medicine at Loyal about the pills.
“I think it’s perfectly appropriate for people who care about their dogs and love their dogs the way you and I do. To look for ways to preserve their health and keep them with them longer. And as long as we’re mindful of their quality of life and their well-being. I think that’s a worthy goal,” he said.
On average, dogs live between 10 and 13 years – it’s even less for big or giant breeds like the Great Dane.
The drug is said to work by interacting with insulin growth factor-1, or IGF-1, a hormone that is thought to both cause dogs to grow and accelerate aging in dogs.
Subscribe to The Briefing, Australia’s fastest-growing news podcast on Listnr today. The Briefing serves up the latest news headlines and a deep dive into a topic affecting you. All in under 20 minutes.